Skip to main content

Hydrodissection

Hydrodissection — submucosal injection of fluid into the vaginal wall to hydraulically separate the vaginal epithelium from the underlying fibromuscular layer — is a commonly used adjunct in vaginal prolapse surgery, with variation in technique and use.[1][2] It serves two purposes at once: it creates a defined dissection plane (between the epithelium and the pubocervical connective tissue anteriorly / rectovaginal septum posteriorly), and, when a vasoconstrictor is added, it provides tamponade and vasoconstriction that reduce intraoperative blood loss. The 2025 Cochrane review found limited perioperative evidence and did not establish clinically meaningful benefit for most interventions. Small hydrodissection studies should not be equated with proof of improved repair success.[1]

This page covers both halves of the topic the bedside decision actually involves: the agent (what to put in the syringe) and the technique (where and how to inject it).

Principle and Purpose​

The injected fluid balloons the submucosa and visually delineates the cleavage plane, so dissection follows hydraulics rather than blind sharp cutting. Adding a vasoconstrictor compresses and constricts the submucosal vessels along that plane. The two goals are partly independent: plain saline can separate the plane; vasoconstrictors may modestly reduce blood loss but introduce systemic cardiovascular risk. Neither approach guarantees a correct plane or improved long-term repair.[1][2]

Technique by Procedure​

Anterior colporrhaphy​

After an Allis clamp is placed on the anterior vaginal wall, solution is injected submucosally along the planned incision and laterally into the vesicovaginal space until the tissue balloons and the plane between epithelium and pubocervical connective tissue is visible. A midline vertical incision is carried through the distended epithelium, then dissection is limited to the extent needed for the planned repair. A routine midline colporrhaphy does not require dissection to the arcus tendineus fascia pelvis.[2][3] A randomized trial (46 patients) found hydrodissection produced significantly less bleeding (ΔHb 0.66 vs 1.21 g/dL, p = 0.05) without degrading the plane — histology showed no difference in connective tissue left at the surgical margin.[2]

Posterior colporrhaphy​

Subepithelial infiltration can facilitate separation of vaginal epithelium from the supporting fibromuscular layer while protecting the rectum. Routine posterior colporrhaphy does not require full-thickness posterior-wall dissection or opening the pararectal space to the sacrospinous ligament; that exposure belongs to separately indicated procedures.[3]

Vaginal hysterectomy​

A pericervical / intracervical circumferential injection before the initial circumferential incision distends the vesicovaginal and rectovaginal planes and eases entry into the anterior and posterior cul-de-sacs. A hysterectomy meta-analysis of 7 RCTs (455 patients; five vaginal and two abdominal trials) found vasopressin-based hydrodissection cut estimated blood loss by a mean of 119.85 mL (95% CI −177.55 to −62.14); an RCT of cervical vasopressin reduced blood loss to ~145 vs 266 mL (p = 0.022).[7][8]

Colpocleisis (LeFort and total)​

Hydrodissection — commonly with lidocaine and epinephrine — precedes excision of the rectangular epithelial patches, lifting the epithelium off the muscularis to give clean planes for the subsequent purse-string plication.[4][5]

Historical vaginal mesh procedures​

Published transvaginal POP-mesh techniques describe normal saline infiltration before the vaginal-wall incision in transobturator/transgluteal and single-incision systems; the described dissection depends on the device. These historical techniques do not establish a current US indication for transvaginal POP mesh.[3]

Injectate Agents and Dilutions​

AgentTypical dilution / doseEffect on blood lossKey consideration
Normal saline aloneVolume tailored to tissue and procedureSmall-trial blood-loss signalBaseline; plane separation without vasoconstriction[1][2]
Saline + epinephrine1:200,000 (5 µg/mL) is one published concentrationDirect vaginal comparative evidence limitedAccount for cardiovascular effects and total dose[10]
Ornipressin (Por-8)5 IU in 100 mL saline (0.05 IU/mL); ~80 mL/compartmentMedian 35 vs 81 mL saline (p = 0.03)No measured BP/pulse difference in one small trial; rare-event safety not established[6]
VasopressinOff-label local injection; concentration and total dose require a defined protocol~120 mL mean reduction in a mixed hysterectomy meta-analysisSerious CV events can occur even with dilute solutions[7][12]
Lidocaine + epinephrineStandard local-anesthetic concentrationsAnalgesia + vasoconstrictionUsed in some colpocleisis techniques; calculate cumulative local-anesthetic dose and LAST risk[4]

A review included 9 RCTs (903 participants); its vasoconstrictor meta-analysis of six RCTs (491 participants) found vasoconstrictive agents (vasopressin/ornipressin) reduced blood loss by an overall ~70 mL (95% CI −125 to −14) versus placebo/saline, with substantial heterogeneity in dose and technique.[11]

Vasopressin​

The most studied agent, given by intracervical/pericervical injection. A meta-analysis (7 RCTs, 455 patients) showed a mean blood-loss reduction of 119.85 mL; a double-blind RCT (117 women) confirmed lower EBL (312 vs 446 mL, p = 0.006) and a smaller hemoglobin drop with no statistically detected increase in pelvic infection (1.6% vs 7.3%).[7][9] It carries the most evidence — and the most cardiovascular risk (below).

Ornipressin (Por-8)​

A synthetic vasopressin analogue with a more selective V1 profile. The only dedicated vaginal-prolapse RCT (80 women, 5 IU/100 mL, 80 mL per compartment) cut median blood loss from 81 to 35 mL (p = 0.03) with no significant change in blood pressure or pulse — this does not establish superior cardiovascular safety or exclude rare severe events. Availability is jurisdiction-specific.[6]

Epinephrine (adrenaline)​

The most universally available additive, typically 1:200,000. No RCT has compared epinephrine to placebo specifically in vaginal prolapse or vaginal hysterectomy; the best comparative data are from myomectomy, where dilute vasopressin and dilute epinephrine produced no difference in blood loss, with transient BP/HR rises only in the epinephrine arm.[10] Do not extrapolate vaginal infiltration practice to penile blocks, compromised flaps or other anatomical sites; use the relevant procedure and local-anesthetic safety guidance.

Head-to-head summary​

VasopressinOrnipressinEpinephrine 1:200,000
CV observationsBradycardia, ischemia and cardiac arrest reportedNo significant BP/HR difference in one small trialBP/HR changes and arrhythmia risk depend on exposure
Rare-event certaintySerious case reports establish need for precautionsTrial too small to establish absence of serious harmsStandard dilution does not eliminate systemic risk
AvailabilityWide (some countries restrict)Not in USUniversal
Evidence in vaginal surgeryMultiple RCTs + 2 meta-analysesSingle RCT (n=80)No vaginal-surgery RCT

The evidence does not establish a best safety-to-efficacy agent. Choose according to procedure, cardiovascular risk, availability and the agreed anesthesia/pharmacy protocol; modest blood-loss changes must be weighed against rare serious harms.[6][7][11]

Cardiovascular Safety — Vasopressin​

The dominant safety concern is vasopressin. Serious events — bradycardia, myocardial ischemia, and cardiac arrest — have been reported even at low concentrations, with cardiac arrest occurring within ~2 minutes of injection, thought to follow inadvertent intravascular injection or rapid absorption; reported laparoscopic/robotic cases do not establish a comparative risk estimate by surgical approach.[12][13][14] Practical precautions:[12][15]

  • Aspirate and inject incrementally; a negative aspiration does not exclude intravascular injection or rapid absorption.
  • Use the lowest effective exposure in a defined local protocol. Neither 0.2 U/mL nor a published total dose is a validated safety threshold.
  • Tell the anesthesia team before injecting; have atropine and resuscitation equipment ready.
  • Extra caution with cardiovascular/coronary disease. ACOG hysteroscopy guidance discusses cautious vasoconstrictor use in that setting; it is not a universal colporrhaphy dosing guideline.[15]

Does Hydrodissection Harm the Repair Plane?​

A recurring worry is that ballooning the submucosa "floats" the fibromuscular layer ("pubocervical fascia," not a true anatomic fascia) off where the surgeon needs it. The small Schwarzman RCT examined a histological surrogate: loose connective tissue at the surgical margin was no different with vs without hydrodissection (13.6% vs 27.3%, p = 0.46) — no difference was detected, but this does not prove equivalent long-term anatomical or functional outcomes.[2] The practical caveat is volume: over-injection, especially in atrophic postmenopausal tissue, can distort planes and make the correct layer harder to find.

Adjacent Considerations​

  • Vaginal microcirculation — incident dark-field imaging shows measurable microvascular change after prolapse surgery (performed with saline + 1:200,000 adrenaline), a tool for studying postoperative vascular damage relevant to mesh erosion and recurrence.[16]
  • Practice variation — a Dutch survey of 133 gynecologists found wide variation in whether and how hydrodissection is used during anterior colporrhaphy, supporting the need to describe the actual technique rather than label it universally standardized.[17]

Practical Pearls​

  • Saline alone is an option — it can facilitate dissection; adding a vasoconstrictor is an individualized decision.[1]
  • Incremental injection, limited exposure, communication with anesthesia whenever vasopressin is used.[12]
  • Inject to balloon, not to flood — enough to define the plane; excess distorts it, worst in atrophic tissue.
  • Match agent to procedure and patient — local analgesia, fluid volume and vasoconstriction are separate choices. Do not use the same recipe for every vaginal repair.

See Also​

References​

1. Shahid U, Haya N, Baessler K, et al. Perioperative interventions in pelvic organ prolapse surgery. Cochrane Database Syst Rev. 2025;7:CD013105. doi:10.1002/14651858.CD013105.pub2

2. Schwarzman P, Samueli B, Shaco-Levy R, et al. The role of hydrodissection in native tissue repair of anterior vaginal wall defects. Aust N Z J Obstet Gynaecol. 2022;62(1):98–103. doi:10.1111/ajo.13431

3. Campagna G, Panico G, Morciano A, et al. Vaginal mesh repair systems for pelvic organ prolapse: anatomical study comparing transobturator/transgluteal versus single-incision techniques. Neurourol Urodyn. 2018;37(3):1024–1030. doi:10.1002/nau.23387

4. Raju R, Occhino JA, Linder BJ. LeFort partial colpocleisis: tips and technique. Int Urogynecol J. 2020;31(8):1697–1699. doi:10.1007/s00192-019-04194-3

5. Linder BJ, Gebhart JB, Occhino JA. Total colpocleisis: technical considerations. Int Urogynecol J. 2016;27(11):1767–1769. doi:10.1007/s00192-016-3034-4

6. Henn EW, Nondabula T, Juul L. Effect of vaginal infiltration with ornipressin or saline on intraoperative blood loss during vaginal prolapse surgery: a randomised controlled trial. Int Urogynecol J. 2016;27(3):407–412. doi:10.1007/s00192-015-2821-7

7. Hafidh B, Latifah HM, Gari A, et al. Vasopressin to control blood loss during hysterectomy: a systematic review and meta-analysis of randomized controlled trials. J Minim Invasive Gynecol. 2022;29(3):355–364.e2. doi:10.1016/j.jmig.2021.10.003

8. Ascher-Walsh CJ, Capes T, Smith J, Michels A. Cervical vasopressin compared with no premedication and blood loss during vaginal hysterectomy: a randomized controlled trial. Obstet Gynecol. 2009;113(2 Pt 1):313–318. doi:10.1097/AOG.0b013e3181954c44

9. Kammerer-Doak DN, Rogers RG, Johnson Maybach J, Traynor Mickelson M. Vasopressin as an etiologic factor for infection in gynecologic surgery: a randomized double-blind placebo-controlled trial. Am J Obstet Gynecol. 2001;185(6):1344–1347. doi:10.1067/mob.2001.119076

10. Song T, Kim MK, Kim ML, et al. Use of vasopressin vs epinephrine to reduce haemorrhage during myomectomy: a randomized controlled trial. Eur J Obstet Gynecol Reprod Biol. 2015;195:177–181. doi:10.1016/j.ejogrb.2015.10.003

11. Cui Y, Chen I, Chernoff A, Clancy A. Effectiveness of prophylactic pharmacological hemostatic agents for reduction of blood loss at vaginal surgery: a systematic review and meta-analysis. Int Urogynecol J. 2023;34(12):2945–2957. doi:10.1007/s00192-023-05614-1

12. Chudnoff S, Glazer S, Levie M. Review of vasopressin use in gynecologic surgery. J Minim Invasive Gynecol. 2012;19(4):422–433. doi:10.1016/j.jmig.2012.03.022

13. Lee GG, Baek SY, Woo Kim T, et al. Cardiac arrest caused by intramyometrial injection of vasopressin during a robotic-assisted laparoscopic myomectomy. J Int Med Res. 2018;46(12):5303–5308. doi:10.1177/0300060518805596

14. Hobo R, Netsu S, Koyasu Y, Tsutsumi O. Bradycardia and cardiac arrest caused by intramyometrial injection of vasopressin during a laparoscopically assisted myomectomy. Obstet Gynecol. 2009;113(2 Pt 2):484–486. doi:10.1097/AOG.0b013e318187e795

15. Committee on Gynecologic Practice. The use of hysteroscopy for the diagnosis and treatment of intrauterine pathology: ACOG Committee Opinion No. 800. Obstet Gynecol. 2020;135(3):e138–e148. doi:10.1097/AOG.0000000000003712

16. Kastelein AW, Diedrich CM, de Waal L, Ince C, Roovers JWR. The vaginal microcirculation after prolapse surgery. Neurourol Urodyn. 2020;39(1):331–338. doi:10.1002/nau.24203

17. Lensen EJ, Stoutjesdijk JA, Withagen MI, Kluivers KB, Vierhout ME. Technique of anterior colporrhaphy: a Dutch evaluation. Int Urogynecol J. 2011;22(5):557–561. doi:10.1007/s00192-010-1353-4